Freenome has entered an exclusive licence agreement with Exact Sciences, granting the latter the rights to commercialise Freenome's blood-based CRC screening test in the US.

Solventum (NYSE:SOLV) shares rose after hours today on second-quarter results that came in ahead of the consensus forecast.

Treace Medical Concepts (TMCI) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to a loss of $0.34 per share a year ago. These ...

Also, Omron’s recent acquisitions increased its product line, allowing the firm to provide tailored automation solutions to customers. Covid-19 provided a strong growth opportunity for Omron’s ...

Experts now better understand the causes of different types of chronic pain. Here's what to know about the treatments that ...

EU Batteries Regulation requires portable batteries in products to be removable, boosting lifespan, recycling & waste ...

Millimeter Wave Technology Market Expected to Reach $17.9 Billion by 2032 ...

A few pieces of wood in a Helena-West Helena garage sparked the creation of a one-of-a-kind medical device company that has ...